Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
Tools to properly select candidates for prostate biopsy after magnetic resonance imaging (MRI) have usually been analyzed in overall populations with suspected prostate cancer (PCa). However, the performance of these tools can change regarding the Prostate Imaging-Reporting and Data System (PI-RADS)...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/11/2702 |
| _version_ | 1797493906324062208 |
|---|---|
| author | Miriam Campistol Juan Morote Marina Triquell Lucas Regis Ana Celma Inés de Torres María E. Semidey Richard Mast Anna Santamaría Jacques Planas Enrique Trilla |
| author_facet | Miriam Campistol Juan Morote Marina Triquell Lucas Regis Ana Celma Inés de Torres María E. Semidey Richard Mast Anna Santamaría Jacques Planas Enrique Trilla |
| author_sort | Miriam Campistol |
| collection | DOAJ |
| description | Tools to properly select candidates for prostate biopsy after magnetic resonance imaging (MRI) have usually been analyzed in overall populations with suspected prostate cancer (PCa). However, the performance of these tools can change regarding the Prostate Imaging-Reporting and Data System (PI-RADS) categories due to the different incidence of clinically significant PCa (csPCa). The objective of the study was to analyze PSA density (PSAD), MRI-ERSPC risk calculator (RC), and Proclarix to properly select candidates for prostate biopsy regarding PI-RADS categories. We performed a head-to-head analysis of 567 men with suspected PCa, PSA > 3 ng/mL and/or abnormal rectal examination, in whom two to four core transrectal ultrasound (TRUS) guided biopsies to PI-RADS ≥ three lesions and/or 12-core TRUS systematic biopsies were performed after 3-tesla mpMRI between January 2018 and March 2020 in one academic institution. The overall detection of csPCa was 40.9% (6% in PI-RADS < 3, 14.8% in PI-RADS 3, 55.3% in PI-RADS 4, and 88.9% in PI-RADS 5). MRI-ERSPC model exhibited a net benefit over PSAD and Proclarix in the overall population. Proclarix outperformed PSAD and MRI-ERSPC RC in PI-RADS ≤ 3. PSAD outperformed MRI-ESRPC RC and Proclarix in PI-RADS > 3, although none of them exhibited 100% sensitivity for csPCa in this setting. Therefore, tools to properly select candidates for prostate biopsy after MRI must be analyzed regarding the PI-RADS categories. While MRI-ERSPC RC outperformed PSAD and Proclarix in the overall population, Proclarix outperformed in PI-RADS ≤ 3, and no tool guaranteed 100% detection of csPCa in PI-RADS 4 and 5. |
| first_indexed | 2024-03-10T01:26:42Z |
| format | Article |
| id | doaj.art-55eda0809eb9441d8fbb82da98dcbd6e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:26:42Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-55eda0809eb9441d8fbb82da98dcbd6e2023-11-23T13:49:46ZengMDPI AGCancers2072-66942022-05-011411270210.3390/cancers14112702Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRIMiriam Campistol0Juan Morote1Marina Triquell2Lucas Regis3Ana Celma4Inés de Torres5María E. Semidey6Richard Mast7Anna Santamaría8Jacques Planas9Enrique Trilla10Department of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainProstate Cancer Research Group, Vall d’Hebron, Research Institute, 08035 Barcelona, SpainProstate Cancer Research Group, Vall d’Hebron, Research Institute, 08035 Barcelona, SpainDepartment of Radiology, Vall d’Hebron Hospital, 08035 Barcelona, SpainProstate Cancer Research Group, Vall d’Hebron, Research Institute, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainTools to properly select candidates for prostate biopsy after magnetic resonance imaging (MRI) have usually been analyzed in overall populations with suspected prostate cancer (PCa). However, the performance of these tools can change regarding the Prostate Imaging-Reporting and Data System (PI-RADS) categories due to the different incidence of clinically significant PCa (csPCa). The objective of the study was to analyze PSA density (PSAD), MRI-ERSPC risk calculator (RC), and Proclarix to properly select candidates for prostate biopsy regarding PI-RADS categories. We performed a head-to-head analysis of 567 men with suspected PCa, PSA > 3 ng/mL and/or abnormal rectal examination, in whom two to four core transrectal ultrasound (TRUS) guided biopsies to PI-RADS ≥ three lesions and/or 12-core TRUS systematic biopsies were performed after 3-tesla mpMRI between January 2018 and March 2020 in one academic institution. The overall detection of csPCa was 40.9% (6% in PI-RADS < 3, 14.8% in PI-RADS 3, 55.3% in PI-RADS 4, and 88.9% in PI-RADS 5). MRI-ERSPC model exhibited a net benefit over PSAD and Proclarix in the overall population. Proclarix outperformed PSAD and MRI-ERSPC RC in PI-RADS ≤ 3. PSAD outperformed MRI-ESRPC RC and Proclarix in PI-RADS > 3, although none of them exhibited 100% sensitivity for csPCa in this setting. Therefore, tools to properly select candidates for prostate biopsy after MRI must be analyzed regarding the PI-RADS categories. While MRI-ERSPC RC outperformed PSAD and Proclarix in the overall population, Proclarix outperformed in PI-RADS ≤ 3, and no tool guaranteed 100% detection of csPCa in PI-RADS 4 and 5.https://www.mdpi.com/2072-6694/14/11/2702clinically significant prostate cancerPSA densityProclarixMRI-ERSPCmagnetic resonance imaging |
| spellingShingle | Miriam Campistol Juan Morote Marina Triquell Lucas Regis Ana Celma Inés de Torres María E. Semidey Richard Mast Anna Santamaría Jacques Planas Enrique Trilla Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI Cancers clinically significant prostate cancer PSA density Proclarix MRI-ERSPC magnetic resonance imaging |
| title | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI |
| title_full | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI |
| title_fullStr | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI |
| title_full_unstemmed | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI |
| title_short | Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI |
| title_sort | comparison of proclarix psa density and mri erspc risk calculator to select patients for prostate biopsy after mpmri |
| topic | clinically significant prostate cancer PSA density Proclarix MRI-ERSPC magnetic resonance imaging |
| url | https://www.mdpi.com/2072-6694/14/11/2702 |
| work_keys_str_mv | AT miriamcampistol comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT juanmorote comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT marinatriquell comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT lucasregis comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT anacelma comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT inesdetorres comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT mariaesemidey comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT richardmast comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT annasantamaria comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT jacquesplanas comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri AT enriquetrilla comparisonofproclarixpsadensityandmrierspcriskcalculatortoselectpatientsforprostatebiopsyaftermpmri |